One of the paradigms for surrogate marker evaluation in clinical trials is based on employing data from several clinical trials: the meta-analytic approach. Originally developed for continuous outcomes by means of the linear mixed model, also other situations are of interest. One such situation is when both outcomes are binary. While joint models have been proposed for this setting, they are cumbersome in the sense of computationally complex and of producing validation measures that are, unlike in the Gaussian case, not of an R 2 type (Burzykowski, Molenberghs, and Buyse 2005). A way to put these problems to rest is by employing information theory, already applied in the continuous case (Alonso and Molenberghs 2007) . In this paper, the information-theoretic approach is applied to the case of binary surrogate and true endpoints. Its use is illustrated using a case study in acute migraine and its performance, relative to existing methods, assessed by means of a simulation study. Since the usefulness of a method critically depends, among others, on the availability of software, a SAS implementation accompanies the methodological work.
Introduction
The use of surrogate endpoints in clinical trials is increasing, necessitating the development of sound statistical methods for use in the evaluation process. The following definitions are in common use (Biomarkers Definition Working Group 2001) . A clinical endpoint is a characteristic or variable that reflects how a patient feels, functions, or survives. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. A surrogate endpoint is a biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit, harm, or lack thereof.
One important reason for the present interest in surrogate endpoints is the advent of a large number of biomarkers that closely reflect the disease process. An increasing number of new drugs have a welldefined mechanism of action at the molecular level, allowing drug developers to measure the effect of these drugs on the relevant biomarkers (Ferentz 2002) . There is increasing public pressure for new, promising drugs to be approved for marketing as rapidly as possible, and such approval will have to be based on biomarkers rather than on some long-term clinical endpoint (Lesko and Atkinson 2001) .If the approval process is shortened, there will be a corresponding need for earlier detection of safety signals that could point to toxic problems with new drugs. It is a safe bet, therefore, that the evaluation of tomorrow's drugs will be based primarily on biomarkers, rather than on the longer-term, harder clinical endpoints that have dominated the development of new drugs until now. It is therefore best to use validated surrogates, though one needs to reflect on the precise meaning and extent of validation (Schatzkin and Gail 2002) . Like in many clinical decisions, statistical arguments will play a major role, but ought to be considered in conjunction with clinical and biological evidence. At the same time, surrogate endpoints can play different roles in different phases of drug development. While it may be more acceptable to use surrogates in early phases of research, one should be much more restraint using them as substitutes for the true endpoint in pivotal phase III trials, since the latter might imply replacing the true endpoint by a surrogate for all future studies as well, a far-reaching decision. For a biomarker to be used as a "valid" surrogate, a number of conditions must be fulfilled. The ICH Guidelines on Statistical Principles for Clinical Trials state that "In practice, the strength of the evidence for surrogacy depends upon (i) the biological plausibility of the relationship, (ii) the demonstration in epidemiological studies of the prognostic value of the surrogate for the clinical outcome and (iii) evidence from clinical trials that treatment effects on the surrogate correspond to effects on the clinical outcome" (International Conference on Harmonisation 1998).
While initially done in the context of a single trial (Prentice 1989 , Freedman, Graubard, and Schatzkin 1992 , Buyse and Molenberghs 1998 , the meta-analytic framework is now a well accepted one. It allows to cast the evaluation in terms of two important concepts and ultimately quantities: trial-level and individual-level surrogacy. Several authors have contributed to its development; a synthesis is provided in Burzykowski, Molenberghs, and Buyse (2005) . Several issues still surround the framework. First, while reasonably feasible for continuous, normally distributed endpoints, thanks to the availability of the linear mixed model (Verbeke and Molenberghs 2000) , the non-Gaussian case is less straightforward, be it for surrogate and true outcomes from the same type or of a different nature. And then even the Gaussian case already needed special attention (Tibaldi et al 2003) . The main issue is that joint models for the outcomes are needed, preferably allowing for the hierarchy induced by disposing of many trials. Second, and related to the previous comment, is that different models produce different validation quantities.
While for the Gaussian case one is led to R 2 type measures, for other settings such measures as odds ratios and Kendall's τ crop up, with the situation getting more complex for longitudinally measured endpoints. Alonso and Molenberghs (2007) , in an effort to alleviate the reported issues, adopted an information theory approach (ITA) to propose an evaluation method that is simple in both use and interpretation of the resulting measures. They applied their ideas to longitudinally measured, continuous endpoints.
In this paper, we will adapt the framework to the situation where both outcomes are binary. The methodology will be introduced in Sections 3 as far as general concepts are concerned and in Section 4 specifically for ITA, and then put to the test in a simulation study (Section 5) and exemplified by means of a case study in acute migraine, introduced in Section 2 and analyzed in Section 6. The work reported here is supplemented with a generic implementation as a SAS macro, available to the interested reader from the authors,
A Meta-analysis of Ten Clinical Trials in Acute Migraine
Consider a meta-analysis of 10 early phase trials assessing the efficacy of several therapies for the treatment of acute migraine crises. Each trial was placebo-controlled and aimed at evaluating one of three experimental treatments. Two trials also included an active control arm. Overall, 801 patients were available, recruited over 38 different centers, with between 1 and 86 patients enrolled per center.
Severity of headache and migraine-related symptoms were measured prior to and at several occasions after the dose administration. Severity was rated on a four-grade intensity scale (0 =no, 1 =mild, 2 =moderate, 3 =severe). Clinically relevant endpoints for efficacy included pain-free (pain score=0) and pain relief (pain score<= 1) two hours post-dose. The main goal is to identify what symptoms typically associate with migraine episodes, such as, for example, nausea, vomiting, increased sensitivity to light, i.e., photophobia, as well as to sound, i.e., phonophobia.
Validation Methods
We review the meta-analytic approach for two binary variables. In line with Renard et al (2002) , it is assumed the binary variables result from dichotomized normally distributed ones, thence concepts of the continuous meta-analytic framework (Buyse et al (2000) can be employed. Extensions of the framework to other settings are brought together in Burzykowski, Molenberghs, and Buyse (2005) . Motivated by the computational complexity of this framework, we will first discuss a number of simplifying strategies (Tibaldi et al 2003) and then move on to the information-theoretic approach of Alonso and Molenberghs (2007) .
The Meta-Analytic Approach for Binary Endpoints
To extend the methodology used for continuous endpoints to the case of binary endpoints , Renard et al (2002) adopted a latent variable approach, resting on the assumption that the observed binary variables result from dichotomizing an unobserved continuous variable based on the threshold chosen. Assume a pair of latent variables ( S ij , T ij ), representing the continuous, underlying values of the surrogate and true endpoints for subject j = 1, . . . , n i in trial i = 1, . . . , N, following a random-effects model at the latent scale:
µ S and µ T are fixed intercepts, α and β are fixed treatment effects, m Si and m T i are random (i.e., trial-specific) intercepts, a i and b i are random treatment effects, and ε Sij and ε T ij are error terms. The random effects are zero-mean normally distributed with covariance matrix
The error terms are also zero-mean normally distributed with covariance matrix:
The implied model for the observed binary outcomes is
where Φ denotes the standard normal cumulative distribution function. Formulation (1)- (3) allows the use of the coefficient of determination
as the trial-level R 2 , whereas the individual-level R 2 indiv is equal to the square of ρ ST . These quantities are unitless and, at the condition that the corresponding variance-covariance matrix is positive definite, belong to the unit interval. A surrogate could thus be adopted when R 2 trial is sufficiently large. Arguably, rather than using a fixed cutoff above which a surrogate would be adopted, there always will be clinical and biopharmaceutical judgment involved in the decision process. It is important to be aware that, rather than solely relying on point estimates, also confidence intervals ought to play a role in such cutoffs.
Note that, here, trial is considered as experimental unit which can be replaced by center, investigator or any other suitable experimental unit, depending on the nature of the study conducted. The issue of the unit of analysis has been thoroughly studied by Cortiñas et al (2004) and Tilahun et al (2007) .
After fitting such models, we thus obtain two measures of surrogacy, captures as trial-level and individuallevel coefficients of determination. A surrogate could be adopted, for clinical trial purposes, when R 2 trial is sufficiently large. Arguably, rather than using a fixed cutoff above which a surrogate would be adopted, there always will be clinical and other judgment involved in the decision process. The R 2 indiv = R 2
is based on Σ.
Parameter Estimation
Model (1)- (3) Assembling all parameters into the vector Θ , the contribution of the ith trial (i = 1, . . . , N) to the
Maximum likelihood estimation follows from integrating (6) over b i , summing over all subjects, taking the logarithm, and maximizing
over Θ. Here, φ(b i ; D) denotes the mean-zero multivariate normal density with covariance matrix D.
The intractable nature of (7) dictates the use of one or other form of approximation, as mentioned earlier. Renard et al (2002) suggested the use of maximum pairwise likelihood (MPL), a pseudolikelihood approach based on replacing the likelihood by a product of conditional and/or marginal densities. In our particular case, the proper likelihood contribution of trial i is replaced by all possible pairwise margins. Detailed overviews of the methodology can be found in Molenberghs and Verbeke (2005) and Burzykowski, Molenberghs, and Buyse (2005) .
Drawbacks and Simplified Modeling Strategies
While it is technically possible to fit the bivariate probit model, the use of which necessitated by the pairwise likelihood approach, there still are a number of drawbacks associated with the approach outlined.
First, the resulting surrogate marker evaluation measures apply to the postulated latent variables rather than to the observed binary variables. Second, the computational burden still is considerable. Third, the approach might result in an ill-conditioned variance-covariance matrix, thence calling the reliability of the association measures derived into question. Some of these problems occur in the continuous case as well, for a discussion of which we refer to Tilahun et al (2007) . To address the problem of computational burden, Tibaldi et al (2003) suggested several simplifications for the case of continuous true and surrogate endpoints. They have organized their simplifications along three so-called dimensions.
Let us outline these in turn and then examine their usefulness for the binary case.
The trial dimension is concerned with whether the random effects are considered fixed or random. If the trial-specific effects are chosen to be fixed, a two-stage approach is effectively adopted. The first-stage model will take the form
where g S and g T are appropriate link functions. At the second stage, the estimated treatment effect on the true endpoint is regressed on the treatment effect and intercept from the surrogate endpoint model:
Here, µ Si , α i , and β i are estimates obtained from (8) and (9), with the λ being regression coefficients estimated using conventional linear regression techniques. The trial-level R 2 trial(f) then is the coefficient of determination obtained by regressing β i on µ Si and α i , whereas R 2 trial(r) is obtained from the coefficient of determination resulting from regressing β i on α i only. The subscripts (f ) and (r) refer to 'full' and 'reduced', respectively. The individual-level measure of surrogacy is then calculated using ITA, to be outlined in Section 4.
The second option is to consider the trial-specific effects as random. How one then proceeds is related to the so-called endpoint dimension. Indeed, though natural to assume the two endpoints correlated, this choice does increase computational complexity. The desirability to accommodate the bivariate nature of the outcome is associated with interest in R 2 indiv , which is in some cases of secondary importance. This applies, for example, when the trial-level surrogacy R 2 trial is the sole quantity of importance to the investigator; this may occur in a clinical trial context, as opposed to when the surrogate is used, for example, for diagnostic purposes. Furthermore, even when the individual-level surrogacy is of importance, there now is the possibility to estimate it by making use of ITA rather than by formulating a bivariate model. If in the trial dimension, the trial-specific effects are considered fixed, then models (8)-(9) are fitted separately. Similarly, if the trial-specific effects are considered random, then the corresponding models
are fitted separately, i.e., the corresponding error terms in the two models are assumed to be independent.
Otherwise, the outcomes are considered correlated and a full mixed-modeling approach is followed.
Except when a bivariate mixed-modeling approach is followed, there is a need to adjust for the heterogeneity in the amount of information contributed by the various trials. This is the subject of the measurement error dimension. One can either ignore this phenomenon of weight the trial-specific contributions according to trial size. This then turns (10) into a weighted regression. Tibaldi et al (2003) also proposed another measure than just trial size as candidate weights, but we will leave these out of consideration.
The Information Theory Approach
As mentioned in the previous section, the main rationale for explicitly accommodating for the two endpoints' correlation is to allow for individual-level surrogacy estimation, at the price of increased computation complexity. It is therefore advantageous to switch towards ITA, which is elegant and computationally simple (Alonso and Molenberghs 2007) . Let us describe the method for the case of generalized linear models, obviously containing bivariate outcomes as a particular instance. Consider the following generalized linear models:
Model (11) relates the expected value of the true endpoint to the treatment only while (12) relates it to surrogate endpoint as well. Upon fitting (11)-(12), the individual-level association can be measured by:
where G 2 i denotes the likelihood ratio statistics to compare (11) and (12) within trial i, the size of which is n i . The subscript h is added to distinguish this quantity from earlier uses of R 2 measures. One issue arising is that, for discrete random variables R 2 h has an upper bound smaller than one, as shown by Alonso and Molenberghs (2007) , who therefore suggested the use of an adjusted version:
where H(y) is the log-likelihood of the true endpoint divided by the total number of subjects. To augment R 2 adj with a measure for uncertainty, Alonso and Molenberghs (2007) suggested asymptotic as well as bootstrap-based intervals.
ITA ideas can be applied to compute the trial-level R 2 trial too, using the fully hierarchical model for continuous outcomes (Buyse et al 2000) . The resulting R 2 h,trial will take the same form as (13), with now G 2 i the likelihood ratio statistics for comparing models relating treatment effect to the true endpoint, with and without adjusting for the surrogate endpoint. Since this second-stage model is for continuous endpoints, the issue of an upper bound smaller than one does not crop up.
Simulation Study
We will now assess the performance of the proposed approach, first laying out the design of our simulation study and then summarizing the results.
Design of Simulation Study
The data were generated based on model (3)-(4). The parameters were set equal to µ S = 0.5, µ T = 0.45, α = 0.05, and β = 0.03. Values assumed for the covariance matrices are:
After generating continuous outcomes based on the above models, the corresponding binary variables are obtained by dichotomizing the resulting continuous outcomes using the fixed intercepts as cut-off points, setting values exceeding the intercept to 1 and 0 otherwise. These model choices imply R 2 trial =0.90 and R 2 indiv = 0.64, at the continuous scale. Given we want to compare a variety of estimation methods, it would be unwieldy to expand the R 2 values into grids. However, the performance relative to these value is of interest, since they are in the range of what is observed for the acute migraine data, as will be shown in Section 6. The important issue can then be raised as to what values should be reached for good surrogacy. These are very difficult to answer purely in statistical terms. However, quantification of surrogacy provides an important piece of evidence when deciding on the adoption of a surrogate; such a decision will clearly also involve biological, biomedical, ethical, and economic arguments.
Simulation Results
The number of trials was fixed to either 5, 10, 20, or 30. There were 2 sets of trial sizes used, the first set consisting of 10, 20, 40 or 60, which we term small trial size. The second set consists of 100, 150, 200 or 300, termed large trial size. A full combination of the number of trials and trial sizes was obtained.
In each case, 100 runs were performed. We further distinguish between the bivariate and univariate models on the one hand, and mixed-versus fixed-effects models on the other hand. The mixed models take the form of the probit model in the bivariate situation and the GLMM in the univariate case. The simulation results, for a small selection set of numbers of trials and trial sizes, are displayed in Tables 1   and 2 . The results shown are representative for those not shown as well.
Let us first consider association at the trial level. The simulation reveal that the full bivariate random effects model and its univariate counterpart are consistent in that both models produce surrogacy measures approaching the true values with the number of trials and the number of subjects increasing.
However, the corresponding fixed-effects models lead to underestimation, even for larger sample sizes.
Even though the full bivariate model leads to measures at the latent scale, since it measures the association between the treatment effects on the two endpoints, we expect it to be preserved at the explicit scale. This claim is corroborated by the results from the univariate mixed model, which operates at the observed binary scale. It is also noteworthy that there is not much difference between the ITA and the conventional approach of regressing the treatment effect on the true endpoint on the treatment effect on the surrogate endpoint. Turning to the individual-level association, the full bivariate random-effects and bivariate fixed-effect models result in individual-level measures close to the true value, i.e., the theoretical value at the latent scale. However, they are hard to translate from the latent scale to the explicit one. ITA is a convenient way out of this problem. An important observation made from the simulation study, that will be confirmed by the data analysis in the next section, is that the values reported with ITA are substantially smaller than their latent counterparts, in line with expectation: switching from the latent scale to the explicitly observed scale reduces association. This is a manifestation of the fact that important information is lost when switching from a continuous to a binary scale. Of course, in a real study, the binary variables are the only ones observed and it is therefore fair to assert that the ITA is a fair representation of reality, whereas the other methods are overly optimistic.
Analysis of Acute Migraine Data
Let us analyze the data described in Section 2, using the methods introduced in Sections 3 and 4. Of the symptoms studied: nausea, vomiting, photophobia, phonophobia, the photophobia symptom had the highest trial-level surrogacy. Results for both the trial-and individual-level surrogacy are presented in Table 3 . For illustration, we also provide the results for phonophobia (Table 4) , which is not retained since the validation measures are consistenly lower. Indeed, while it might be considered acceptable, if it were the only candidate available, we now conclude, by comparison, that photophobia is the winner.
Both point estimates as well as 95% confidence intervals are presented. Observe that the univariate and bivariate fixed-effects models result in smaller R 2 trial than the random-effects counterpart. However, the latter is unreliable since based on an ill-conditioned covariance matrix, in the sense of a grossly inflated leading eigenvalue. Basing our conclusions on the univariate mixed effect model, in the simulations found to work well, it is fair to assert that, at the trial level, the presence of photophobia is a good surrogate for migraine severity, i.e., the corresponding R 2 trial may be considered sufficiently high. The reasonably good agreement between the treatment effects at both levels, and in addition the absence of obvious outliers, is clear from Figure 1 , a so-called bubble plot, displaying a scatter of the pairs of treatment effects for each unit. The size of the circles, or bubbles, is proportional to the number of patients per unit.
The R 2 indiv for the bivariate fixed and mixed models are higher than their univariate counterparts. This is expected for the same reason as explained in Section 5, i.e., one is at the latent scale, whereas the ITA works at the interpretationally more relevant explicitly observed scale.
Discussion
In this paper, we reviewed the meta-analytic strategy by Buyse et al (2000) , its extension to binary endpoints, and the information theoretic approach for validating surrogate endpoints. The application of the latter framework with binary data is novel. The meta-analytic approach and its extension are mathematically appealing, but encounter practical and/or computational issues. The information theoretic approach involves substantial mathematics yet it is more practically feasible than the meta-analytic approach as it depends on simple univariate models. In addition, the initial meta-analytic framework, where individual-level surrogacy is expressed at the latent probit level, leads to overestimation of the said quantity. Since the ITA operates at the explicitly observed scale, it provides a fairer and more useful quantity.
Additionally, the computational complexity of the full random-effects meta-analytic framework has led to the use of simplifying frameworks, trading the random effects for fixed effects on the one hand and/or bivariate, joint modeling of both endpoints by two univariate, separate models. These simplifications work well when the number of trials and the number of subjects per trials is large, indicating one should in practice carefully consider the unit of analysis. Of course, the choice of unit has also implications in terms of substantive interpretation, as elucidated in Cortiñas et al (2004) .
Applying the proposed methodology to acute migraine trial data has shown that photophobia is a reasonably good surrogate at the trial level, whereas it surrogacy at the individual level may be called into question. This finding is of interest and may spark of further investigation from a clinical and biopharmaceutical perspective.
Absence of standard software has been one of the limiting factors hampering the use of the meta-analytic approach. The authors have developed a SAS macro for the calculations laid out in the paper, and details are to be found in the Appendix.
Clearly, the use of validation methods, such as the ones proposed in this paper, whether based on R 2 , other association measures, or ITA, is but one component of the broader surrogacy picture. All methods discussed here fall within the meta-analytic framework. This is also true for the recent work by Baker (2006) , who proposed the use of average prediction error based on relatively straightforward regression models. Also, regardless of the framework within which one is working, once a surrogate has been adopted, or even before, it is important to assess how it will perform in a new trial. Burzykowski and Buyse (2006) proposed the so-called surrogate threshold effect (STE). Their method is intended to derive a sample size large enough for a treatment effect on the surrogate endpoints to translate into a meaningful and significant effect on the true endpoint. 
A Implementations
Let us briefly outline the use of the SAS macro SURBINBIN that can be used to perform the analyses described in this paper. The macro is invoked in the following fashion:
%surbinbin (response=,endpoint=,trial=,subject=,data=,trt=,adj=, initfix=,initd=,initcorr=,red=,type=,dmat=,outf= ,plot=,drive=,file=,solutionf=) where es response: Name of the response variable.
endpoint: Name of the endpoint indicator (−1 =surrogate endpoint, 1 =true endpoint).
trial: Name of the unit of analysis (center, trial,. . . ). subject: Name of the variable indicating the unique subject identification number. data: Name of the input dataset. See the macro description on data formatting and layout for further detail.
trt: Name of the treatment indicator variable. adj: A choice for using weighted (adj= 1)or unweighted(adj= 0) regression at the second stage, i.e., the choice made along the measurement error dimension. red: A choice for using reduced (red= 1) or full (red= 0) model, i.e., whether or not the random intercept is taken into account when calculating R 2 trial .
initd: If type is set to 4, this string is used to enter initial values for the covariance matrix D of random effects. The elements of the lower-triangular part are to be listed by row.
initfix: If type is set to 4, this string is used to enter initial values for the fixed-effects parameters (mu S , beta S , mu T , and beta T ).
crit: If type is set to 4, this string is used to enter the absolute parameter convergence criterion. The default value is 0.0001.
initcorr: If type is set to 4, this string is used to enter initial values for ρ, i.e., the residual correlation parameter.
type: A choice for using the different modeling approaches (1-4):
1. univariate fixed effects;
2. bivariate fixed effects;
3. univariate random effects;
4. bivariate random effects.
dmat: A choice for printing the matrix of the random terms to the output file (1 =yes, 0 =no).
solutionf: A choice for printing the solution for fixed effect to the output file (1 =yes, 0 =no).
outf: A choice for printing the trial specific random effects, for type= 3, or fixed effects, for type= 1 or 2, to the output file (1 =yes, 0 =no).
plot:
A choice for printing the plot of the raw outcomes, residuals and treatment effects of the main endpoint against those of the surrogate endpoint (plot= 1).
drive:
The drive on the computer where the user wants to save the output file (e.g., A, C, or D).
file: The name of the output file containing the macro results.
rescale: The option to control the size of the bubble plots when the treatment effects on the true endpoint are plotted against those of the surrogate endpoints. It can take integer values or fractions depending on the size of the plots. It is important that the endpoint indicator be coded as −1/ + 1, with 1 indicating the true endpoint. 
